Sarepta (SRPT) Bullish View Reiterated at Needham & Company on Expanded European DMD Pipeline

Needham & Company analyst Chad Messer reiterated a Buy rating and $81 price target on Sarepta Therapeutic (NASDAQ: SRPT) as the company expands its European DMD pipeline with the ezutromid deal.

Messer commented, "Sarepta is acquiring EU rights to Duchenne's muscular dystrophy (DMD) treatment ezutromid from Summit Therapeutics for $40M upfront. While we do not forecast ezutromid approval until at least 2019, the deal gives SRPT another shot on goal and we believe helps establish it as a leader in DMD therapy. Perhaps as important, we expect the collaboration to accelerate development of combination therapies which we expect will become the standard of care in DMD in the future. Notably, Sarepta also recently signed a collaboration agreement with Catabasis to study their NF-kB targeted DMD therapy in combination with Exondys 51. We maintain our Buy rating and $81 price target. Separately, we introduce a new model for US Exondys launch."

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $62.35 yesterday.

You May Also Be Interested In

• Needham Upgrades Silicon Labs (SLAB) to Buy
• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
• CONMED (CNMD) PT Lowered to $107 at Needham